The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 ...

Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. | Despite making up a sizable ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...